Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Targeted Molecular Diagnostics has launched KRAS Mutation assay, a new clinical laboratory test, to identify colorectal cancer patients who may be resistant to EGFR targeted monoclonal antibody therapies.
Subscribe to our email newsletter
Targeted Molecular Diagnostics’s (TMD) KRAS Mutation assay (DxS Diagnostics), utilizes SNP-based Real-Time PCR technology to identify seven of the most common KRAS mutations in DNA from frozen or formalin fixed paraffin embedded (FFPE) tumor specimens.
The company is said to have selected a Real-Time PCR platform to overcome the sensitivity concerns associated with sequencing technologies that have been reported in the literature. The results of the assay are available within eight to 10 days from receipt of the specimen at TMD. TMD provides specimen collection kits for convenient collection and shipment of specimens.
TMD’s KRAS Mutation assay may help identify patients who harbor specific KRAS mutations and therefore may not respond to EGFR inhibitors.